ישראל - עברית - Ministry of Health

medison pharma ltd - siltuximab - אבקה להכנת תמיסה מרוכזת לעירוי - siltuximab 100 mg - siltuximab

ישראל - עברית - Ministry of Health

medison pharma ltd - siltuximab - אבקה להכנת תמיסה מרוכזת לעירוי - siltuximab 400 mg

ישראל - עברית - Ministry of Health

merck serono ltd - cetuximab - תמיסה לאינפוזיה - cetuximab 5 mg/ml - cetuximab - cetuximab - erbitux® is indicated for the treatment of patients with epidermal growth factor receptor (egfr) - expressing, kras wild-type metastatic colorectal cancer• in combination with irinotecan-based chemotherapy• in first-line in combination with folfox• as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecanerbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck (scchn)• in combination with radiation therapy for locally advanced disease• in combination with platinum-based chemotherapy for recurrent and/or metastatic disease• as a single agent after failure of platinum-based chemotherapy for recurrent and/or metastatic disease

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - rituximab - תרכיז להכנת תמיסה לאינפוזיה - rituximab 10 mg/ml - rituximab - rituximab - mabthera is indicated for the following indications: * non-hodgkin’s lymphoma (nhl)mabthera is indicated for the treatment of patients with relapsed or refractory low-grade or follicular, b-cell non-hodgkin’s lymphoma.mabthera is indicated for the treatment of previously untreated patients with low-grade or follicular lymphoma in combination with chemotherapy mabthera is indicated for the treatment of patients with cd20 positive diffuse large b-cell non-hodgkin's lymphoma in combination with chop chemotherapy. mabthera maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy. * chronic lymphocytic leukaemia (cll)mabthera in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including mabthera or patients refractory to previous mabthera plu

ישראל - עברית - Ministry of Health

padagis israel agencies ltd, israel - rituximab - תרכיז להכנת תמיסה לאינפוזיה - rituximab 10 mg/ml - rituximab

ישראל - עברית - Ministry of Health

medison pharma ltd - dinutuximab beta - תרכיז להכנת תמיסה לאינפוזיה - dinutuximab beta 4.5 mg / 1 ml - dinutuximab

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - rituximab - תמיסה להזרקה - rituximab 1400 mg / 11.7 ml - rituximab

ישראל - עברית - Ministry of Health

novartis israel ltd - rituximab - תרכיז להכנת תמיסה לאינפוזיה - rituximab 10 mg / 1 ml - rituximab

ישראל - עברית - Ministry of Health

sanofi israel ltd - isatuximab - תרכיז להכנת תמיסה לאינפוזיה - isatuximab 20 mg / 1 ml - isatuximab

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - rituximab - תרכיז להכנת תמיסה לאינפוזיה - rituximab 10 mg/ml - rituximab